摘要
髓系白血病有很多好的分子靶点,而且许多针对这些靶点的新药正在临床试验当中。随着后基因时代的到来,将会找出更多的新靶点,将会出现更多的靶点治疗药物。芯片和蛋白质组学技术的发展有可能有利于找到个体化靶点治疗的具体方案。髓系白血病分子靶点治疗是一个重要的研究方向。
出处
《国外医学（输血及血液学分册）》
2005年第5期449-452,共4页
Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
参考文献29
-
1Alison M, John N,Shaun B, et al. Targeted therapies in myeloid leukemia. Semin Cancer Biol, 2004,14 ( 1 ) : 41-62.
-
2Liu P, Han ZC. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol, 2003,78(1):32-39.
-
3Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.Leukemia ,2003,17(8) : 1454-1463.
-
4Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-transretinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol, 2003, 21(12) : 2326-2334.
-
5Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase Ⅰ study of imatinib(STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2002 (10), 38(Suppl 5) :S83-87.
-
6Dagher R, Cohen M, Williams G, et al. Approval summary:imatinib mesylate in the treatmentof metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res ,2002,8(10) : 3034-3038.
-
7George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol, 2003, 532:141-151.
-
8Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patientswith chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med, 2002,347(7):481-487.
-
9Thiede C, Steudel C, Mohr B,et al. Analysis of FLT3-activating mutations in 979 patientswith acute myelogenous leukemia:association with FAB subtypes and identification of subgroups with poor prognosis. Blood,2002,99(12) :4326-4335.
-
10Gutkind JS. Cell growth control by G protein-coupled receptors:from signal transduction to signal integration. Oncogene, 1998,17(11):1331-1342.
同被引文献1
-
1靳凤艳,邹德慧,王国蓉,徐燕,冯四洲,赵耀中,韩明哲,严文伟,邱录贵.成人急性淋巴细胞白血病缓解后化疗和自体造血干细胞移植疗效的比较[J].中华血液学杂志,2005,26(11):645-648. 被引量：17
-
1王辰生,李红方,梁冰锋.胃癌及区域淋巴结中Fas和FasL的表达与临床生物学行为关系研究[J].河北医药,2013,35(11):1637-1639. 被引量：1
-
2曹莉莎,王继生.蛋白质组学在药物研究中的应用[J].中国医药指南,2013,11(36):366-368.
-
3张晓实.鼻咽癌分子靶点治疗和免疫治疗研究进展[J].肿瘤学杂志,2008,14(1):32-34.
-
4任蕴芳,唐佩弦.髓系白血病细胞分化诱导剂的研究进展[J].国外医学（药学分册）,1989,16(4):200-204.
-
5赵艳霞,刘文励.血液系统恶性疾病的蛋白组学研究[J].临床血液学杂志,2005,18(5):314-316. 被引量：1
-
6钟狂飚,蒋先镇.蛋白质组学在前列腺肿瘤研究中的应用[J].国外医学（泌尿系统分册）,2005,25(2):148-152.
-
7黄猛.后基因组时代药物研究的新领域——蛋白质组学[J].中国生化药物杂志,2004,25(2):109-111. 被引量：3
-
8孙丽,邹鹏.蛋白质芯片SELDI—TOF MS技术在肿瘤蛋白质组学的研究进展[J].丹东医药,2006(2):5-8.
-
9程磊,周梁.蛋白质组学研究进展及在头颈肿瘤标志物筛选中的应用[J].国际耳鼻咽喉头颈外科杂志,2006,30(1):1-4. 被引量：1
-
10靳智勇.HDGF与恶性肿瘤研究进展[J].疾病监测与控制,2009,3(4):245-248.
